<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047656</url>
  </required_header>
  <id_info>
    <org_study_id>CLFF269X2105</org_study_id>
    <nct_id>NCT02047656</nct_id>
  </id_info>
  <brief_title>To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension</brief_title>
  <official_title>A Two Part Study Including a Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LFF269 After b.i.d Dosing in Healthy Volunteers and an Open Label, Multiple Dose Pharmacokinetics Study in Hypertension Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to enable optimal dose selection of LFF269 for potential future
      studies by providing additional information about the compounds safety, tolerability,
      pharmacokinetic and pharmacodynamic profiles.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of healthy volunteers reported with adverse events as an assessment of safety and tolerability (Part 1)</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau)[Part 1- Healthy volunteers]</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed maximum plasma concentration following drug administration (Cmax) at day 1 [Part 1- Healthy volunteers]</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau (AUCtau) [Part 2- Patients with hypertension]</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed maximum plasma concentration following drug administration (Cmax) at day 1 [Part 2 - Patients with hypertension]</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau at steady state (AUCtau,ss) [Part 1- Healthy volunteers]</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau at steady state (AUCtau,ss) [Part 2 - Patients with hypertension]</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed maximum plasma concentration following drug administration at steady state (Cmax,ss) [Part 2 - Patients with hypertension]</measure>
    <time_frame>Up to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed maximum plasma concentration following drug administration at steady state (Cmax,ss) [Part 1- Healthy volunteers]</measure>
    <time_frame>Up to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients reported with adverse events as an assessment of safety and tolerability (Part - 2, Patient with Hypertension)</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Part 1 - Healthy Volunteers</condition>
  <condition>Part 2 - Patients With Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo to LFF269 (Part 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to LFF269 twice daily (b.i.d) for 10 days in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LFF269 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LFF269 twice daily (b.i.d) for 10 days in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LFF269 (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LFF269 twice daily (b.i.d) for 5 days in patients with hypertension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LFF269</intervention_name>
    <description>LFF269 capsules twice daily (b.i.d)</description>
    <arm_group_label>LFF269 (Part 1)</arm_group_label>
    <arm_group_label>LFF269 (Part 2)</arm_group_label>
    <other_name>LFF269 active</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to LFF269</intervention_name>
    <description>Placebo LFF269 b.i.d for 10 days in healthy volunteers</description>
    <arm_group_label>Placebo to LFF269 (Part 1)</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part 1

        - Healthy men and women of non-childbearing potential, 18 to 80 years of age inclusive, and
        in good health as determined by past medical history, physical examination, vital signs,
        electrocardiogram, and laboratory tests at screening.

        Part 2

          -  Hypertensive men and women of non-childbearing potential, 18 to 80 years of age
             inclusive.

          -  Patients with mild-to-moderate uncomplicated essential hypertension

        Exclusion Criteria:

        Part 1

          -  History of hypersensitivity or allergy to any of the study drugs or to drugs of
             similar chemical classes.

          -  A history of clinically significant ECG abnormalities.

          -  Known history or current clinically significant arrhythmias.

          -  History of hypertension, adrenal or endocrine disease.

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive hCG laboratory test.

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant.

          -  Smokers (use of tobacco products in the previous 3 months).

          -  History of immunodeficiency diseases, including a positive HIV (ELISA and Western
             blot) test result.

          -  A positive Hepatitis B surface antigen or Hepatitis C test result.

        Part 2

          -  Pregnant or nursing (lactating) women.

          -  Women of child-bearing potential.

          -  Known history or evidence of a secondary form of hypertension

          -  Type 1 or type 2 diabetes mellitus.

          -  History of heart diseases

          -  A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.

          -  History of immunodeficiency diseases, including a positive HIV (ELISA and Western
             blot) test result.

        Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2014</study_first_submitted>
  <study_first_submitted_qc>January 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <last_update_submitted>March 30, 2016</last_update_submitted>
  <last_update_submitted_qc>March 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers, hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

